Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1), its ligand (PD-L1), cytotoxic T-lymphocyte associated protein-4 (CTLA-4) or lymphocyte activation gene-3 have improved the survival of patients with multiple cancer types. Here, CTLA4 is linked to cancer.